Total Wealth Planning & Management Inc. Sells 3,602 Shares of Gilead Sciences, Inc. $GILD

Total Wealth Planning & Management Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,746 shares of the biopharmaceutical company’s stock after selling 3,602 shares during the period. Total Wealth Planning & Management Inc.’s holdings in Gilead Sciences were worth $1,005,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of GILD. Client 1ST Advisory Group LLC increased its position in shares of Gilead Sciences by 4.0% in the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 69 shares in the last quarter. Grove Bank & Trust raised its stake in shares of Gilead Sciences by 1.2% in the 3rd quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after acquiring an additional 74 shares during the period. Financial Connections Group Inc. lifted its holdings in shares of Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 76 shares in the last quarter. Wilkerson Advisory Group LLC lifted its holdings in shares of Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 78 shares in the last quarter. Finally, HBW Advisory Services LLC lifted its holdings in shares of Gilead Sciences by 2.4% during the 1st quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock valued at $473,000 after acquiring an additional 79 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the insider owned 113,684 shares of the company’s stock, valued at $17,759,714.48. The trade was a 2.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at $1,459,771.32. This represents a 33.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock worth $15,877,860 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on GILD shares. Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. HSBC raised their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $159.81.

Gilead Sciences Stock Performance

GILD opened at $156.04 on Monday. The firm has a market capitalization of $193.48 billion, a P/E ratio of -58.44 and a beta of 0.31. The firm’s 50 day moving average is $149.10 and its 200-day moving average is $137.84. Gilead Sciences, Inc. has a 52-week low of $114.02 and a 52-week high of $160.51. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 earnings per share. Analysts expect that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
• Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
• Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
• Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
• Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.